文献速递淋巴瘤

大剂量化疗联合自体造血干细胞支持治疗复发或难治性原发性中枢神经系统淋巴瘤:德国PCNSL协作组的前瞻性多中心试验

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
PubMed 文献 · Leukemia · 2017-05-31

这项单臂多中心研究纳入39例≤66岁、对大剂量甲氨蝶呤为基础化疗失败的免疫功能正常的复发/难治性原发性中枢神经系统淋巴瘤患者,采用利妥昔单抗、大剂量阿糖胞苷和塞替派诱导后行含利妥昔单抗、卡莫司汀和塞替派的HCT-ASCT。HCT-ASCT后56.4%达完全缓解,2年PFS 46.0%、OS 56.4%,记录4例治疗相关死亡。作者认为塞替派为基础的HCT-ASCT是符合条件的复发/难治性PCNSL患者的有效治疗选择,需比较研究进一步明确其解救治疗作用。

要点

  • 39例复发/难治性PCNSL患者接受塞替派为基础HCT-ASCT,HCT-ASCT后完全缓解率56.4%。
  • 2年无进展生存率46.0%(中位12.4个月),2年总生存率56.4%,中位总生存未达到。
  • 记录4例治疗相关死亡;作者认为需比较研究进一步明确HCT-ASCT在解救治疗中的作用。

核心结论

  • 塞替派为基础的HCT-ASCT是符合条件的复发/难治性PCNSL患者的有效治疗选择,需比较研究进一步明确其在解救治疗中的作用。

研究设计与样本

  • 单臂多中心研究,纳入39例≤66岁、对大剂量甲氨蝶呤为基础化疗失败的免疫功能正常的复发/难治性PCNSL患者。
  • 诱导为两疗程利妥昔单抗375 mg/m2、大剂量阿糖胞苷2×3 g/m2和塞替派40 mg/m2,期间采集干细胞。
  • HCT-ASCT预处理为利妥昔单抗375 mg/m2、卡莫司汀400 mg/m2和塞替派4×5 mg/kg,诱导后无论疗效均开始HCT-ASCT。

主要发现

  • 中位年龄57岁,中位Karnofsky体能状态评分90%;28例为复发、8例为难治性疾病。
  • 22例对诱导有反应,32例开始HCT-ASCT;22例(56.4%)在HCT-ASCT后达到完全缓解。
  • 2年无进展生存率46.0%(中位无进展生存12.4个月),2年总生存率56.4%,中位总生存未达到。
  • 记录4例治疗相关死亡。

关键数值与推荐

  • HCT-ASCT后完全缓解率为56.4%(22/39)。
  • 2年无进展生存率46.0%,中位无进展生存12.4个月;2年总生存率56.4%,中位总生存未达到。

临床怎么用

  • 作者认为塞替派为基础的HCT-ASCT是符合条件的复发/难治性PCNSL患者的有效治疗选择;原文未据此给出具体推荐。

局限性

  • 原文报告4例治疗相关死亡。
  • 原文结论指出需比较研究进一步明确HCT-ASCT在解救治疗中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017. PMID: 28559537. doi:10.1038/leu.2017.170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。